Overview
U.S. proteomics platform's Q1 revenue fell 34% yr/yr amid funding and competitive pressures
Adjusted EPS for Q1 was negative, reflecting lower revenue and reduced operating expenses
Company repurchased 1.5 mln shares and ended Q1 with $220 mln in cash and investments
Outlook
Seer expects full-year 2026 revenue between $16 mln and $18 mln
Result Drivers
DEPRESSED ACADEMIC FUNDING - Co said lower Q1 revenue was primarily due to continued depressed academic funding environment
INCREASED COMPETITION - Co cited competitive activity in the proteomics space as a factor in lower Q1 revenue
LOWER OPERATING EXPENSES - Q1 operating expenses decreased mainly due to lower employee compensation, including stock-based compensation
Company press release: ID:nGNX6YmYfD
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$2.79 mln
Q1 EPS
-$0.30
Q1 Net Income
-$16.84 mln
Q1 Gross Margin
35%
Q1 Gross Profit
$982,000
Q1 Operating Expenses
$18.24 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the office equipment peer group is "buy"
Wall Street's median 12-month price target for Seer Inc is $4.00, about 119.8% above its May 12 closing price of $1.82
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)